Sam Brusco, Associate Editor11.07.22
NeuroMetrix has strategically launched its Quell Fibromyalgia device through the Pathfinder Program. According to the company, it’s the first and only medical device FDA authorized to reduce fibromyalgia symptoms.
The Quell Fibromyalgia device uses transcutaneous electrical nerve stimulation (TENS) to be an aid in reducing fibromyalgia symptoms in adults with high pain sensitivity. It can be used during sleep, as well.
NeuroMetrix aims to have full commercial launch of Quell Fibromyalgia in Q2 2023. Pathfinder begins December 1 and will be limited to 25 key opinion leaders in fibromyalgia practice across the U.S.
“We are excited to initiate the Pathfinder Program,” Shai N. Gozani, M.D., Ph.D., CEO of NeuroMetrix told the press. “By partnering with these physicians, some of the most forward-thinking clinicians on the front lines of fibromyalgia, we will clarify our messaging and distribution process to increase market access and ultimately give patients the best chance of success with our technology.”
The Quell Fibromyalgia device uses transcutaneous electrical nerve stimulation (TENS) to be an aid in reducing fibromyalgia symptoms in adults with high pain sensitivity. It can be used during sleep, as well.
NeuroMetrix aims to have full commercial launch of Quell Fibromyalgia in Q2 2023. Pathfinder begins December 1 and will be limited to 25 key opinion leaders in fibromyalgia practice across the U.S.
“We are excited to initiate the Pathfinder Program,” Shai N. Gozani, M.D., Ph.D., CEO of NeuroMetrix told the press. “By partnering with these physicians, some of the most forward-thinking clinicians on the front lines of fibromyalgia, we will clarify our messaging and distribution process to increase market access and ultimately give patients the best chance of success with our technology.”